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Ongoing monocyte infiltration and subsequent macrophage seeding of adipose tissue is thought to be a key
feature of obesity pathophysiology. Nagareddy et al. (2014) show that adipose cells locally activate IL-1b in
macrophages in part through the alarmin S100A8/A9, which stimulates bone marrow myelopoiesis to
perpetuate nonresolving inflammation.Obesity is a form of nonresolving inflam-
mation because the insulting entity,
excess fat, is not removed from the
body. Other forms of nonresolving inflam-
mation include cancer (ongoing growth
of malignant tissue), atherosclerosis
(cholesterol crystals), neurological pathol-
ogies (amyloid and other agents that
cannot be removed from the brain), latent
and long-lived infections (tuberculosis,
leprosy), autoimmune diseases (Crohn’s
disease, for example), and scenarios in
which entities cannot be removed (foreign
bodies such as medical devices) or
asbestos (Nathan andDing, 2010). Under-
standing nonresolving inflammation is
critical from a public health perspective,
because this type of inflammation is
linked to the major diseases afflicting
modern societies. The nonresolving
inflammation of obesity is associated
with a maladaptive local immune
response characterized by increased
numbers of activated macrophages
inside adipose tissue. In this issue of Cell
Metabolism, Nagareddy et al. (2014)
define a regulatory loop in which inflamed
adipose tissue and the bone marrow (BM)
communicate via IL-1b, causing seeding
of fat with monocytes.
The biology of nonresolving inflamma-
tion centers on the sequence of events
after attempts by the immune response
to eliminate the inciting entity. Links
between local immune responses, hema-
topoiesis, and nonresolving inflammation
have been recognized, especially in
cancer where myeloid-derived suppres-
sor cells (MDSCs) are associated with
malignancy, originate in the BM, and
represent excessive ‘‘emergency hema-
topoiesis’’ to clear the insult (Gabrilovich
et al., 2012). A model for the involvement
of BM in nonresolving inflammation
includes corrupted hematopoiesis, inwhich excess myeloid cells are released
into the circulation. Increased myeloid
output may contribute to unresolved
inflammatory responses in each pathol-
ogy listed above, but vary in their timing
and amplitude depending on the underly-
ing disease.
A landmark in understanding obesity
was the recognition that ‘‘inflamed’’ mac-
rophages associated with obese but not
healthy adipose tissue (Weisberg et al.,
2003). Macrophages invading adipose
tissue originate from the BM and are
thought to perpetuate the local maladap-
tive inflammatory response. Therefore, a
significant question in the field of obesity
research, and indeed in nonresolving
inflammation in general, concerns the
chicken-and-egg scenario linking inflam-
mation and the disease: Is inflammation
necessary to perpetuate the pathology,
or a product of disease with other ramifi-
cations? A related question concerns the
timing and extent of therapies to abate
inflammation in unresolved disease, and
their consequences should the underlying
insult remain. So far, these events cannot
readily be separated, because modeling
or dissecting an inflammatory-linked dis-
ease cannot be done in the absence of
inflammation.
Nagareddy et al. first showed that
genetically obese Ob/Ob mice or mice
with diet-induced obesity (DIO) have
enhanced production of myeloid precur-
sors in the BM, a reversible process in
DIO when animals were returned to a
normal diet (Nagareddy et al., 2014). The
numbers of committed myeloid progeni-
tors and granulocyte-macrophage pro-
genitors were higher in Ob/Ob mice
reconstituted with wild-type BM, indi-
cating the presence of excess fat is a
driver of myelopoiesis, rather than the
underlying genotype. These data wereCell Metabolisbuttressed by transplanting fat tissue
from visceral adipose tissue of lean mice
or Ob/Ob mice. Indeed, fat transplanta-
tion was an ingenious method used to
tease apart several of the key mecha-
nisms involved in the signals sent
between adipose tissue and the BM.
Knowing there may be factors made in
fat capable of directly or indirectly
inducing myelopoiesis, Nagareddy et al.
screened for relative increases in different
inflammatory factors in visceral fat of
obese mice compared to controls from
lean mice. The authors centered on the
high relative mRNA expression of the
cytoplasmic calcium-binding ‘‘alarmins’’
S100A8/A9. Reasoning S100A8/A9 might
be a local inflammatory signal provoking
inflammation, they tested the effects of
loss-of-function mutants on fat-induced
myelopoeisis using TLR4, a receptor
capable of interacting with S100A8/A9,
RAGE (another receptor capable of bind-
ing S100 proteins), Myd88, CD14, and
the NLRP3 inflammasome. By screening
different reciprocal BM and fat trans-
plants, Nagareddy et al. established that
fat-derived S100A8/A9 is a local stimulant
of macrophage TLR4-Myd88 to increase
IL-1b mRNA. The IL-1b precursor is pro-
cessed by the NLRP3 inflammasome to
produce mature IL-1b, which transits to
the BM to provoke myelopoiesis. One of
the key experiments described was the
transplantation of visceral fat from Ob/
Obmice where macrophages were selec-
tively depleted by liposomes loaded with
the bisphosphonate toxin, clodronate.
Macrophage-depleted fat failed to drive
myelopoiesis to the same extent as
macrophage-replete fat from lean mice.
While Nagareddy et al. have revealed
new details about fat-BM communication,
several elements of the pathway require
elaboration. First, other hematopoieticm 19, May 6, 2014 ª2014 Elsevier Inc. 735
Figure 1. Different Cytokines Have
Overlapping and Complementary Effects
of Hematopoiesis Depending on the
Inflammatory Context
Shown is a highly simplified diagram of the
hematopoietic tree along the myeloid lineage
where different cytokines propel cell production
forward. Nagareddy et al. (2014) show that IL-1b,
via the IL-1R, primarily effects CMP/GMP stages,
producing monocytes that seed adipose tissue.
IL-1R signaling has previously been shown to
control neutrophil production in alum-induced
inflammation (Ueda et al., 2009). G-CSF has a
broad role in overall myelopoiesis, while IFN
signaling seems to regulate HSCs.
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Previewsfactors are likely involved in the process,
not just IL-1b, as the effects observed on
myelopoiesis were relative changes in
the amplitude of the response. Contribu-
tion from other cytokines could include
inflammation-induced G-CSF, CSF-1,
and GM-CSF, whose placement into the
overall pathway requires definition. The736 Cell Metabolism 19, May 6, 2014 ª2014same group recently showed that GM-
CSF and CSF-1 are drivers of myelopoie-
sis in hyperglycemia; S100A8/A9 also
stimulates this pathway, but in this case
the alarmins originate from neutrophils
and signal via RAGE (Nagareddy et al.,
2013). A second caveat concerns the
final fate of the monocytes, which
seed and develop into fat-associated
macrophages: since the process is
ongoing in nonresolving inflammation,
and occurs over time frames of months
to years, one possibility is that macro-
phage death is also a component of the
inflammatory process. The elimination
of macrophage corpses, themselves
likely loaded with other corpses, is a rela-
tively unexplored component of nonre-
solving inflammation.
Nagareddy et al. clearly place IL-1b as
a systemic hormone capable of stimu-
lating myelopoiesis. How does IL-1b fit
into the bigger puzzle of long-range in-
flammatory stimulation of the hemato-
poiesis (Figure 1)? Other studies have
shown IL-1b as a key cytokine to stimu-
late granulopoiesis in alum-induced
inflammation via stimulation of multiple
points on the hematopoietic tree,
including early stem cells (Ueda et al.,
2009), while the type I and type II
(IFN-g) interferons have selective effects
on early stem cells, provoking their divi-
sion in infection to produce more innate
inflammatory cells (King and Goodell,
2011). Work from the Link laboratory
has shown that G-CSF appears to modu-
late multiple levels of the hematopoietic
tree; although the end product of
G-CSF therapy is recorded as increases
in circulating neutrophils, the effects of
G-CSF on hematopoiesis, and myelopoi-
esis especially, are broad (Richards et al.,Elsevier Inc.2003). Taken together, different phases
of inflammation regulate hematopoiesis
differentially, governed by the predomi-
nant circulating cytokines, and producing
cells according to need (Figure 1). A sim-
ple model would be inflammatory cyto-
kine control of blood cell development
evolved coincident with infection.
However, in nonresolving forms of inflam-
mation, many of which arise later in life
(obesity, atherosclerosis, cancer), the
production of innate hematopoietic cells
from the BM becomes corrupted by
circulating cytokines, which would nor-
mally be transiently produced. Further
investigation of the interaction points
between systemic inflammatory cyto-
kines and the hematopoietic system
will provide new insights into chronic
inflammation.
REFERENCES
Gabrilovich, D.I., Ostrand-Rosenberg, S., and
Bronte, V. (2012). Nat. Rev. Immunol. 12, 253–268.
King, K.Y., and Goodell, M.A. (2011). Nat. Rev.
Immunol. 11, 685–692.
Nagareddy, P.R., Murphy, A.J., Stirzaker, R.A., Hu,
Y., Yu, S., Miller, R.G., Ramkhelawon, B., Distel, E.,
Westerterp, M., Huang, L.S., et al. (2013). Cell
Metab. 17, 695–708.
Nagareddy, P.R., Kraakman, M., Masters, S.L.,
Stirzaker, R.A., Gorman, D.J., Grant, R.W., Drag-
oljevic, D., Hong, E.S., Abdel-Latif, A., Smyth,
S.S., et al. (2014). Cell Metab. 19, this issue,
821–835.
Nathan, C., and Ding, A. (2010). Cell 140, 871–882.
Richards, M.K., Liu, F., Iwasaki, H., Akashi, K., and
Link, D.C. (2003). Blood 102, 3562–3568.
Ueda, Y., Cain, D.W., Kuraoka, M., Kondo, M., and
Kelsoe, G. (2009). J. Immunol. 182, 6477–6484.
Weisberg, S.P., McCann, D., Desai, M., Rose-
nbaum, M., Leibel, R.L., and Ferrante, A.W., Jr.
(2003). J. Clin. Invest. 112, 1796–1808.
